ScholarIQanswers from OpenAlex & ORCID
Chiara Cremolini
ResearcherPublications, citations & collaboration network
Chiara Cremolini is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Chiara Cremolini have?
ScholarIQindexed works
Chiara Cremolini has 987 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Chiara Cremolini have?
ScholarIQcitation count
Chiara Cremolini has 21,459 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Chiara Cremolini?
ScholarIQh-index
Chiara Cremolini has an h-index of 67 in OpenAlex.
What is the i10-index of Chiara Cremolini?
ScholarIQi10-index
Chiara Cremolini has an i10-index of 249 in OpenAlex.
What is the ORCID of Chiara Cremolini?
ScholarIQorcid
The ORCID for Chiara Cremolini is on the source record.
What is the OpenAlex record for Chiara Cremolini?
ScholarIQopenalex
The OpenAlex for Chiara Cremolini is on the source record.
What are the most-cited papers on Chiara Cremolini?
ScholarIQmost cited works
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D’Amico, Cristina Granetto, Marina Elena Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, D. Amoroso, Silvana Chiara, Chiara Carlomagno, C. Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila, Sara Lonardi, Elena Conca, Marzia Del Re, Adele Busico, Filippo Pietrantonio, Romano Danesi, Giuseppe Aprile, Emiliano Tamburini, Carlo Barone, Gianluca Masi, Francesco Pantano, Francesca Pucci, Domenico Corsi, Nicoletta Pella, Francesca Bergamo, Eleonora Rofi, C. Barbara, Alfredo Falcone, Daniele Santini
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis, Luca Emanuele Pollina, I. Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone